Top

Published in:

Open Access 01-05-2014 | Preclinical study

MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis

Authors: Fan Yang, Xingchun Zhou, Xia Miao, Tao Zhang, Xiaojun Hang, Ru Tie, Nan Liu, Fei Tian, Fuli Wang, Jianlin Yuan

Published in: Breast Cancer Research and Treatment | Issue 1/2014

Abstract

MAGEC2 is a member of melanoma antigen (MAGE) family of cancer-testis antigens and associated with tumor relapse and metastasis. Here, we investigated the expression of MAGEC2 in patients with breast cancer and its clinical effects with underlying mechanisms. The expression levels of MAGEC2 were compared between 420 invasive ductal carcinoma (IDC) and 120 ductal carcinoma in situ of the breast. Correlations between MAGEC2 expression and clinico-pathologic factors or survival of patients with IDC were analyzed. In addition, MAGEC2 expression levels in tumor tissues dissected from the primary focus and matched tumor-invaded axillary lymph nodes were analyzed in 8 breast cancer patients. The functional effects of MAGEC2 overexpression were assessed in vitro using scratch assay and transwell chamber assay. MAGEC2 expression was increased in metastatic breast cancer in comparison to the non-metastatic. MAGEC2 expression was significantly associated with ER negative expression (P = 0.037), high tumor grade (P = 0.014) and stage (P = 0.002), high incidence of axillary lymph node metastasis (P = 0.013), and distant metastasis (P = 0.004). Patients with tumor with MAGEC2 positive expression have a worse prognosis and a shorter metastasis free interval. Multivariate analyses showed that MAGEC2 expression was an independent risk factor for patient overall survival and metastasis-free survival. Breast cancer cells that overexpressed MAGEC2 had stronger migratory and invasive potential than control-treated cells. Epithelial markers (E-cadherin and cytokeratin) were down-regulated in MAGEC2-overexpressing cells compared to controls, whereas mesenchymal markers (vimentin and fibronectin) were upregulated. Our results indicate that MAGEC2 has a role in breast cancer metastasis through inducing epithelial-mesenchymal transition. In addition, MAGEC2 is a novel independent poor prognostic factor in patients with IDC. Thus, targeting MAGEC2 may provide a novel therapeutic strategy for breast cancer treatment.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. doi:10.3322/caac.20107 PubMedCrossRef

Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127(4):679–695. doi:10.1016/j.cell.2006.11.001 PubMedCrossRef

Savagner P (2001) Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 23(10):912–923. doi:10.1002/bies.1132 PubMedCrossRef

Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454. doi:10.1038/nrc822 PubMedCrossRef

Thompson EW, Newgreen DF, Tarin D (2005) Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer res 65(14):5991–5995. doi:10.1158/0008-5472.CAN-05-0616 PubMedCrossRef

Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2):131–142. doi:10.1038/nrm1835 PubMedCrossRef

Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7(6):415–428. doi:10.1038/nrc2131 PubMedCrossRef

Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890. doi:10.1016/j.cell.2009.11.007 PubMedCrossRef

Peinado H, Portillo F, Cano A (2004) Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48(5–6):365–375. doi:10.1387/ijdb.041794hp PubMedCrossRef

10.

De Craene B, Gilbert B, Stove C, Bruyneel E, van Roy F, Berx G (2005) The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program. Cancer Res 65(14):6237–6244. doi:10.1158/0008-5472.CAN-04-3545 PubMedCrossRef

11.

Moreno-Bueno G, Cubillo E, Sarrio D, Peinado H, Rodriguez-Pinilla SM, Villa S, Bolos V, Jorda M, Fabra A, Portillo F, Palacios J, Cano A (2006) Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res 66(19):9543–9556. doi:10.1158/0008-5472.CAN-06-0479 PubMedCrossRef

12.

Qiao B, Johnson NW, Chen X, Li R, Tao Q, Gao J (2011) Disclosure of a stem cell phenotype in an oral squamous cell carcinoma cell line induced by BMP-4 via an epithelial-mesenchymal transition. Oncol Rep 26(2):455–461. doi:10.3892/or.2011.1299 PubMed

13.

Coradini D, Fornili M, Ambrogi F, Boracchi P, Biganzoli E (2012) TP53 mutation, epithelial-mesenchymal transition, and stemlike features in breast cancer subtypes. J Biomed Biotechnol 2012:254085. doi:10.1155/2012/254085 PubMedCentralPubMedCrossRef

14.

Costa FF, Le Blanc K, Brodin B (2007) Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells 25(3):707–711. doi:10.1634/stemcells.2006-0469 PubMedCrossRef

15.

Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B (2005) Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 65(6):2207–2215. doi:10.1158/0008-5472.CAN-04-1882 PubMedCrossRef

16.

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038):1643–1647PubMedCrossRef

17.

Kasuga C, Nakahara Y, Ueda S, Hawkins C, Taylor MD, Smith CA, Rutka JT (2008) Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy Laboratory investigation. J Neurosurg Pediatr 1(4):305–313. doi:10.3171/PED/2008/1/4/305 PubMedCrossRef

18.

Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, Mirlacher M, Gambazzi F, Harder F, Heberer M, Sauter G, Spagnoli GC (2002) Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 236(6):785–793. doi:10.1097/01.SLA.0000036266.09823.6C PubMedCentralPubMedCrossRef

19.

Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y et al (1995) Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63(3):375–380PubMedCrossRef

20.

Brichard VG, Lejeune D (2007) GSK’s antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 25(Suppl 2):B61–B71. doi:10.1016/j.vaccine.2007.06.038 PubMedCrossRef

21.

Liu W, Cheng S, Asa SL, Ezzat S (2008) The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res 68(19):8104–8112. doi:10.1158/0008-5472.CAN-08-2132 PubMedCrossRef

22.

Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ, Altorki NK (2005) Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 11(22):8055–8062. doi:10.1158/1078-0432.CCR-05-1203 PubMedCrossRef

23.

Miranda EI (2010) MAGE, biological functions and potential clinical applications. Leuk Res 34(9):1121–1122. doi:10.1016/j.leukres.2010.03.045 PubMedCrossRef

24.

Gure AO, Stockert E, Arden KC, Boyer AD, Viars CS, Scanlan MJ, Old LJ, Chen YT (2000) CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. Int J Cancer 85(5):726–732PubMedCrossRef

25.

Zhou X, Yang F, Zhang T, Zhuang R, Sun Y, Fang L, Zhang C, Ma Y, Huang G, Ma F, Song C, Jin B (2013) Heterogeneous expression of CT10, CT45 and GAGE7 antigens and their prognostic significance in human breast carcinoma. Jpn J Clin Oncol 43(3):243–250. doi:10.1093/jjco/hys236 PubMedCrossRef

26.

Bode PK, Barghorn A, Fritzsche FR, Riener MO, Kristiansen G, Knuth A, Moch H (2011) MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors. Mod Pathol 24(6):829–835PubMedCrossRef

27.

von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Hermanns T, Sulser T, Jungbluth AA, Old LJ, Kristiansen G, van den Broek M, Moch H, Knuth A, Wild PJ (2011) MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer. PLoS One 6(7):e21366. doi:10.1371/journal.pone.0021366 CrossRef

28.

Pabst C, Zustin J, Jacobsen F, Luetkens T, Kroger N, Schilling G, Bokemeyer C, Sauter G, Atanackovic D, Marx A (2010) Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma. Exp Mol Pathol 89(2):175–181. doi:10.1016/j.yexmp.2010.06.011 PubMedCrossRef

29.

Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, Hoda SA, Simpson AJ, Old LJ, Caballero O, Neville AM (2011) Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One 6(3):e17876. doi:10.1371/journal.pone.0017876 PubMedCentralPubMedCrossRef

30.

Adams S, Greeder L, Reich E, Shao Y, Fosina D, Hanson N, Tassello J, Singh B, Spagnoli GC, Demaria S, Jungbluth AA (2011) Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? Cancer Immunol Immunother 60(7):999–1007. doi:10.1007/s00262-011-1005-7 PubMedCentralPubMedCrossRef

31.

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844–847PubMedCrossRef

32.

Zhuang R, Zhu Y, Fang L, Liu XS, Tian Y, Chen LH, Ouyang WM, Xu XG, Jian JL, Gure AO, Fortunato S, Ritter G, Old LJ, Simpson AJ, Chen YT, Jin B, Jungbluth AA (2006) Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2. Cancer immun 6:7PubMed

33.

Sakaguchi H, Fujimoto J, Hong BL, Tamaya T (2007) Clinical implications of osteopontin in metastatic lesions of uterine cervical cancers. Cancer Lett 247(1):98–102. doi:10.1016/j.canlet.2006.03.026 PubMedCrossRef

34.

Zhou YC, Liu JY, Li J, Zhang J, Xu YQ, Zhang HW, Qiu LB, Ding GR, Su XM, Mei S, Guo GZ (2011) Ionizing radiation promotes migration and invasion of cancer cells through transforming growth factor-beta-mediated epithelial-mesenchymal transition. Int J Radiat Oncol Biol Phys 81(5):1530–1537. doi:10.1016/j.ijrobp.2011.06.1956 PubMedCrossRef

35.

Tang HR, Luo XQ, Xu G, Wang Y, Feng ZJ, Xu H, Shi YW, Zhang Q, Wu LG, Xue CQ, Wang CW, Wu CY (2012) High mobility group-box 3 overexpression is associated with poor prognosis of resected gastric adenocarcinoma. World J Gastroenterol 18(48):7319–7326. doi:10.3748/wjg.v18.i48.7319 PubMedCentralPubMedCrossRef

36.

Curioni-Fontecedro A, Nuber N, Mihic-Probst D, Seifert B, Soldini D, Dummer R, Knuth A, van den Broek M, Moch H (2011) Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients. PLoS One 6(6):e21418. doi:10.1371/journal.pone.0021418 PubMedCentralPubMedCrossRef

37.

Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9(1):R6. doi:10.1186/bcr1639 PubMedCentralPubMedCrossRef

38.

Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, Brasseur F, Lethe B, De Plaen E, Velu T, Boon T, Coulie PG (2005) High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201(2):241–248. doi:10.1084/jem.20041379 PubMedCentralPubMedCrossRef

39.

Straetemans T, van Brakel M, van Steenbergen S, Broertjes M, Drexhage J, Hegmans J, Lambrecht BN, Lamers C, van Der Bruggen P, Coulie PG, Debets R (2012) TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin Dev Immunol 2012:586314. doi:10.1155/2012/586314 PubMedCentralPubMedCrossRef

40.

Xiao TZ, Bhatia N, Urrutia R, Lomberk GA, Simpson A, Longley BJ (2011) MAGE I transcription factors regulate KAP1 and KRAB domain zinc finger transcription factor mediated gene repression. PLoS One 6(8):e23747. doi:10.1371/journal.pone.0023747 PubMedCentralPubMedCrossRef

41.

Yang B, O’Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann FM, Peng H, Ivanov AV, Simpson AJ, Longley BJ (2007) MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 67(20):9954–9962. doi:10.1158/0008-5472.CAN-07-1478 PubMedCrossRef

42.

Cheung PY, Yip YL, Tsao SW, Ching YP, Cheung AL (2011) Id-1 induces cell invasiveness in immortalized epithelial cells by regulating cadherin switching and Rho GTPases. J Cell Biochem 112(1):157–168. doi:10.1002/jcb.22911 PubMedCrossRef

43.

Cubillo E, Diaz-Lopez A, Cuevas EP, Moreno-Bueno G, Peinado H, Montes A, Santos V, Portillo F, Cano A (2013) E47 and Id1 interplay in epithelial-mesenchymal transition. PLoS One 8(3):e59948. doi:10.1371/journal.pone.0059948 PubMedCentralPubMedCrossRef

44.

Tobin NP, Sims AH, Lundgren KL, Lehn S, Landberg G (2011) Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer 11:417. doi:10.1186/1471-2407-11-417 PubMedCentralPubMedCrossRef

45.

Venkov CD, Link AJ, Jennings JL, Plieth D, Inoue T, Nagai K, Xu C, Dimitrova YN, Rauscher FJ, Neilson EG (2007) A proximal activator of transcription in epithelial-mesenchymal transition. J Clin Investig 117(2):482–491. doi:10.1172/JCI29544 PubMedCentralPubMedCrossRef

46.

Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715. doi:10.1016/j.cell.2008.03.027 PubMedCentralPubMedCrossRef

47.

Ohman Forslund K, Nordqvist K (2001) The melanoma antigen genes–any clues to their functions in normal tissues? Exp Cell Res 265(2):185–194. doi:10.1006/excr.2001.5173 PubMedCrossRef

48.

Chen YT, Chiu R, Lee P, Beneck D, Jin B, Old LJ (2011) Chromosome X-encoded cancer/testis antigens show distinctive expression patterns in developing gonads and in testicular seminoma. Hum Reprod 26(12):3232–3243. doi:10.1093/humrep/der330 PubMedCrossRef

Title: MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis
Authors: Fan Yang
Xingchun Zhou
Xia Miao
Tao Zhang
Xiaojun Hang
Ru Tie
Nan Liu
Fei Tian
Fuli Wang
Jianlin Yuan
Publication date: 01-05-2014
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-014-2915-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Additional value of F-18 FDG PET/CT for initial staging in breast cancer with clinically negative axillary nodes

Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, α9 nicotinic acetylcholine receptor and STAT3

Long-term risk of medical conditions associated with breast cancer treatment

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients

Examining and predicting drug preferences of patients with metastatic breast cancer: using conjoint analysis to examine attributes of paclitaxel and capecitabine

Contribution of problem-solving skills to fear of recurrence in breast cancer survivors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer